David F Claxton

17PUBLICATIONS
74CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene expression (incl. microarray and other genome-wide approaches)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.

Neil D Palmisiano, Ju-Whei Lee, David F Claxton

|Jan 23, 2024
Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia.

Seema Naik, Kevin Rakszawski, Hong Zheng

|Dec 23, 2023
Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.

Johnson Ung, Su-Fern Tan, Todd E Fox

|Nov 07, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus

|Sep 15, 2023
Acute Myeloid Leukemia Causes T Cell Exhaustion and Depletion in a Humanized Graft-versus-Leukemia Model.

Bei Jia, Chenchen Zhao, Kentaro Minagawa

|Nov 23, 2022
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation.

Brynn Levy, Linda B Baughn, Yassmine Akkari

Pageof 3

Frequent Collaborators

3 joint publications

Selina M Luger

3 joint publications

Todd D Schell

2 joint publications

Johnson Ung

2 joint publications

Kevin Rakszawski